Stem definition | Drug id | CAS RN |
---|---|---|
1783 | 17560-51-9 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.78 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
BA (Bioavailability) | 65 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.05 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 27, 1973 | FDA | UCB INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Fluid retention | 246.41 | 16.51 | 164 | 14584 | 50485 | 50539891 |
Cardiac failure congestive | 236.43 | 16.51 | 196 | 14552 | 84186 | 50506190 |
Hypervolaemia | 235.73 | 16.51 | 125 | 14623 | 25374 | 50565002 |
Pulmonary arterial hypertension | 229.48 | 16.51 | 114 | 14634 | 20205 | 50570171 |
Right ventricular failure | 170.10 | 16.51 | 86 | 14662 | 15807 | 50574569 |
Dyspnoea | 139.57 | 16.51 | 411 | 14337 | 547197 | 50043179 |
Drug ineffective | 119.97 | 16.51 | 45 | 14703 | 819288 | 49771088 |
Pulmonary hypertension | 106.92 | 16.51 | 84 | 14664 | 33333 | 50557043 |
Acute kidney injury | 98.76 | 16.51 | 210 | 14538 | 227848 | 50362528 |
Oedema | 92.43 | 16.51 | 108 | 14640 | 70073 | 50520303 |
Oedema peripheral | 92.15 | 16.51 | 165 | 14583 | 157796 | 50432580 |
Calcium deficiency | 70.20 | 16.51 | 21 | 14727 | 929 | 50589447 |
Electrolyte imbalance | 70.17 | 16.51 | 50 | 14698 | 17119 | 50573257 |
Death | 62.22 | 16.51 | 222 | 14526 | 325157 | 50265219 |
Gastrointestinal haemorrhage | 60.94 | 16.51 | 90 | 14658 | 73231 | 50517145 |
Acute respiratory failure | 58.78 | 16.51 | 56 | 14692 | 28726 | 50561650 |
Dyspnoea exertional | 57.90 | 16.51 | 73 | 14675 | 51160 | 50539216 |
Cardiac failure acute | 55.87 | 16.51 | 33 | 14715 | 8217 | 50582159 |
Off label use | 55.54 | 16.51 | 35 | 14713 | 474391 | 50115985 |
Renal failure | 54.10 | 16.51 | 105 | 14643 | 106528 | 50483848 |
Hospitalisation | 53.04 | 16.51 | 81 | 14667 | 67856 | 50522520 |
Hypoxia | 51.76 | 16.51 | 69 | 14679 | 51054 | 50539322 |
Cardiac failure | 50.22 | 16.51 | 84 | 14664 | 75956 | 50514420 |
Pulmonary oedema | 49.47 | 16.51 | 66 | 14682 | 48872 | 50541504 |
Atrial fibrillation | 48.96 | 16.51 | 98 | 14650 | 101647 | 50488729 |
Hypokalaemia | 48.78 | 16.51 | 90 | 14658 | 87902 | 50502474 |
Chronic kidney disease | 43.87 | 16.51 | 56 | 14692 | 39715 | 50550661 |
Hypotension | 43.51 | 16.51 | 159 | 14589 | 235310 | 50355066 |
Torsade de pointes | 42.76 | 16.51 | 32 | 14716 | 11803 | 50578573 |
Transfusion | 42.46 | 16.51 | 33 | 14715 | 12872 | 50577504 |
Rheumatoid arthritis | 41.79 | 16.51 | 5 | 14743 | 202545 | 50387831 |
Gout | 41.41 | 16.51 | 31 | 14717 | 11439 | 50578937 |
Hyperkalaemia | 41.34 | 16.51 | 60 | 14688 | 48029 | 50542347 |
Dermatitis exfoliative | 41.33 | 16.51 | 23 | 14725 | 5119 | 50585257 |
BRASH syndrome | 40.89 | 16.51 | 10 | 14738 | 203 | 50590173 |
Respiratory failure | 39.36 | 16.51 | 84 | 14664 | 91097 | 50499279 |
Blood potassium decreased | 39.14 | 16.51 | 51 | 14697 | 36894 | 50553482 |
Ascites | 38.77 | 16.51 | 50 | 14698 | 35811 | 50554565 |
Cor pulmonale | 38.49 | 16.51 | 16 | 14732 | 1871 | 50588505 |
Cholecystitis | 38.27 | 16.51 | 32 | 14716 | 13839 | 50576537 |
Arthralgia | 38.24 | 16.51 | 43 | 14705 | 438659 | 50151717 |
Urine chloride decreased | 38.15 | 16.51 | 8 | 14740 | 78 | 50590298 |
Joint swelling | 36.44 | 16.51 | 13 | 14735 | 245273 | 50345103 |
Metabolic alkalosis | 35.85 | 16.51 | 17 | 14731 | 2714 | 50587662 |
Urine sodium decreased | 33.16 | 16.51 | 8 | 14740 | 153 | 50590223 |
Alopecia | 33.12 | 16.51 | 15 | 14733 | 245032 | 50345344 |
Contraindicated product administered | 32.45 | 16.51 | 3 | 14745 | 148955 | 50441421 |
Rash | 30.90 | 16.51 | 50 | 14698 | 437421 | 50152955 |
Chest pain | 29.77 | 16.51 | 116 | 14632 | 176766 | 50413610 |
Therapeutic product effect decreased | 28.95 | 16.51 | 3 | 14745 | 136047 | 50454329 |
Oxygen consumption increased | 28.92 | 16.51 | 16 | 14732 | 3520 | 50586856 |
Cardiac arrest | 28.29 | 16.51 | 70 | 14678 | 83581 | 50506795 |
Blood creatinine increased | 28.19 | 16.51 | 66 | 14682 | 76094 | 50514282 |
Pain in jaw | 27.44 | 16.51 | 44 | 14704 | 38384 | 50551992 |
Weight increased | 27.42 | 16.51 | 124 | 14624 | 201767 | 50388609 |
Cardiorenal syndrome | 26.96 | 16.51 | 9 | 14739 | 570 | 50589806 |
Respiratory disorder | 26.92 | 16.51 | 39 | 14709 | 31148 | 50559228 |
Synovitis | 25.67 | 16.51 | 3 | 14745 | 123862 | 50466514 |
Hyperthyroidism | 25.44 | 16.51 | 24 | 14724 | 12151 | 50578225 |
Pericardial haemorrhage | 25.22 | 16.51 | 11 | 14737 | 1447 | 50588929 |
Pericardial effusion | 25.06 | 16.51 | 34 | 14714 | 25555 | 50564821 |
Drug intolerance | 24.43 | 16.51 | 17 | 14731 | 219087 | 50371289 |
Renal impairment | 24.20 | 16.51 | 62 | 14686 | 75599 | 50514777 |
Blood urea increased | 24.11 | 16.51 | 32 | 14716 | 23553 | 50566823 |
Dehydration | 24.05 | 16.51 | 98 | 14650 | 152351 | 50438025 |
Bone density decreased | 23.46 | 16.51 | 22 | 14726 | 11053 | 50579323 |
Paracentesis | 22.93 | 16.51 | 9 | 14739 | 907 | 50589469 |
Arthropathy | 22.38 | 16.51 | 9 | 14739 | 157897 | 50432479 |
Toxic epidermal necrolysis | 22.26 | 16.51 | 29 | 14719 | 20963 | 50569413 |
Localised oedema | 21.80 | 16.51 | 15 | 14733 | 4852 | 50585524 |
Atrial flutter | 21.69 | 16.51 | 19 | 14729 | 8744 | 50581632 |
Neutropenia | 21.69 | 16.51 | 8 | 14740 | 147957 | 50442419 |
Pulmonary arterial pressure increased | 21.65 | 16.51 | 13 | 14735 | 3335 | 50587041 |
Discomfort | 21.55 | 16.51 | 3 | 14745 | 108377 | 50481999 |
Multiple organ dysfunction syndrome | 21.27 | 16.51 | 46 | 14702 | 50291 | 50540085 |
Abdominal distension | 20.54 | 16.51 | 57 | 14691 | 72846 | 50517530 |
Musculoskeletal stiffness | 20.49 | 16.51 | 6 | 14742 | 128475 | 50461901 |
Vascular parkinsonism | 20.24 | 16.51 | 5 | 14743 | 106 | 50590270 |
Oxygen therapy | 19.94 | 16.51 | 10 | 14738 | 1802 | 50588574 |
Orthopnoea | 19.70 | 16.51 | 15 | 14733 | 5674 | 50584702 |
Cellulitis | 19.60 | 16.51 | 55 | 14693 | 70743 | 50519633 |
Pulmonary arterial wedge pressure increased | 19.46 | 16.51 | 6 | 14742 | 294 | 50590082 |
Chronic obstructive pulmonary disease | 19.43 | 16.51 | 46 | 14702 | 53389 | 50536987 |
Oxygen saturation decreased | 19.40 | 16.51 | 56 | 14692 | 73192 | 50517184 |
Device leakage | 19.27 | 16.51 | 15 | 14733 | 5863 | 50584513 |
Blood aldosterone abnormal | 18.81 | 16.51 | 4 | 14744 | 42 | 50590334 |
Elephantiasis | 18.13 | 16.51 | 3 | 14745 | 6 | 50590370 |
Brain natriuretic peptide increased | 18.07 | 16.51 | 13 | 14735 | 4514 | 50585862 |
Blood potassium increased | 17.93 | 16.51 | 23 | 14725 | 16375 | 50574001 |
Hepatic enzyme increased | 17.64 | 16.51 | 9 | 14739 | 137371 | 50453005 |
Renal disorder | 17.63 | 16.51 | 30 | 14718 | 27475 | 50562901 |
Condition aggravated | 17.53 | 16.51 | 147 | 14601 | 296911 | 50293465 |
Asthenia | 17.32 | 16.51 | 155 | 14593 | 318887 | 50271489 |
Epistaxis | 17.03 | 16.51 | 49 | 14699 | 63905 | 50526471 |
Restlessness | 16.85 | 16.51 | 28 | 14720 | 25145 | 50565231 |
Pleural effusion | 16.71 | 16.51 | 57 | 14691 | 81397 | 50508979 |
Haemodialysis | 16.55 | 16.51 | 16 | 14732 | 8346 | 50582030 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiac failure congestive | 231.51 | 18.01 | 209 | 11160 | 76372 | 29486786 |
Acute kidney injury | 166.65 | 18.01 | 334 | 11035 | 264933 | 29298225 |
Hypokalaemia | 111.76 | 18.01 | 116 | 11253 | 50087 | 29513071 |
Fluid retention | 107.95 | 18.01 | 82 | 11287 | 23478 | 29539680 |
Hypervolaemia | 84.65 | 18.01 | 63 | 11306 | 17482 | 29545676 |
Pulmonary hypertension | 83.54 | 18.01 | 64 | 11305 | 18544 | 29544614 |
Hypotension | 81.51 | 18.01 | 209 | 11160 | 194145 | 29369013 |
Cardiac failure | 73.91 | 18.01 | 119 | 11250 | 79168 | 29483990 |
Pulmonary arterial hypertension | 60.59 | 18.01 | 37 | 11332 | 7412 | 29555746 |
Dyspnoea | 58.57 | 18.01 | 264 | 11105 | 326468 | 29236690 |
Oedema peripheral | 57.01 | 18.01 | 124 | 11245 | 103433 | 29459725 |
Oedema | 53.99 | 18.01 | 72 | 11297 | 40411 | 29522747 |
Blood creatinine increased | 52.75 | 18.01 | 107 | 11262 | 84995 | 29478163 |
Right ventricular failure | 48.84 | 18.01 | 33 | 11336 | 7857 | 29555301 |
Chronic kidney disease | 44.37 | 18.01 | 62 | 11307 | 36354 | 29526804 |
Blood potassium increased | 44.10 | 18.01 | 40 | 11329 | 14611 | 29548547 |
Venous pressure jugular increased | 41.05 | 18.01 | 14 | 11355 | 715 | 29562443 |
Weight increased | 37.89 | 18.01 | 88 | 11281 | 76579 | 29486579 |
Hypovolaemia | 36.81 | 18.01 | 28 | 11341 | 8017 | 29555141 |
Drug ineffective | 36.60 | 18.01 | 52 | 11317 | 363118 | 29200040 |
Polyuria | 34.52 | 18.01 | 26 | 11343 | 7336 | 29555822 |
Glomerular filtration rate decreased | 34.38 | 18.01 | 31 | 11338 | 11235 | 29551923 |
Necrotising oesophagitis | 33.25 | 18.01 | 11 | 11358 | 511 | 29562647 |
Renal failure | 32.66 | 18.01 | 110 | 11259 | 118489 | 29444669 |
Generalised oedema | 32.65 | 18.01 | 30 | 11339 | 11135 | 29552023 |
Off label use | 32.37 | 18.01 | 41 | 11328 | 300759 | 29262399 |
Hyponatraemia | 31.63 | 18.01 | 76 | 11293 | 67557 | 29495601 |
Blood pressure systolic decreased | 31.02 | 18.01 | 19 | 11350 | 3825 | 29559333 |
Transfusion | 30.34 | 18.01 | 24 | 11345 | 7274 | 29555884 |
Dehydration | 30.34 | 18.01 | 105 | 11264 | 114643 | 29448515 |
Blood urea increased | 30.05 | 18.01 | 45 | 11324 | 28067 | 29535091 |
Gastrointestinal haemorrhage | 29.59 | 18.01 | 82 | 11287 | 79451 | 29483707 |
Venous pressure jugular decreased | 28.85 | 18.01 | 6 | 11363 | 41 | 29563117 |
Syncope | 28.42 | 18.01 | 82 | 11287 | 81289 | 29481869 |
Orthopnoea | 25.69 | 18.01 | 18 | 11351 | 4542 | 29558616 |
Cellulitis | 24.15 | 18.01 | 54 | 11315 | 45786 | 29517372 |
Blood potassium decreased | 24.12 | 18.01 | 30 | 11339 | 15704 | 29547454 |
Peripheral swelling | 22.02 | 18.01 | 64 | 11305 | 63675 | 29499483 |
Febrile neutropenia | 21.72 | 18.01 | 8 | 11361 | 112232 | 29450926 |
Asthenia | 21.58 | 18.01 | 149 | 11220 | 215101 | 29348057 |
Azotaemia | 21.15 | 18.01 | 16 | 11353 | 4541 | 29558617 |
Dizziness | 20.62 | 18.01 | 134 | 11235 | 189550 | 29373608 |
Blood loss anaemia | 20.23 | 18.01 | 19 | 11350 | 7247 | 29555911 |
Chronic obstructive pulmonary disease | 20.19 | 18.01 | 47 | 11322 | 40908 | 29522250 |
Atrial fibrillation | 19.99 | 18.01 | 87 | 11282 | 105559 | 29457599 |
Brain natriuretic peptide increased | 19.96 | 18.01 | 15 | 11354 | 4215 | 29558943 |
Burkholderia test positive | 19.78 | 18.01 | 9 | 11360 | 990 | 29562168 |
Neutropenia | 18.69 | 18.01 | 14 | 11355 | 131697 | 29431461 |
Acute respiratory failure | 18.50 | 18.01 | 35 | 11334 | 26367 | 29536791 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiac failure congestive | 403.26 | 15.02 | 354 | 23359 | 130226 | 64344793 |
Fluid retention | 314.81 | 15.02 | 222 | 23491 | 59384 | 64415635 |
Hypervolaemia | 283.21 | 15.02 | 176 | 23537 | 38109 | 64436910 |
Pulmonary arterial hypertension | 254.36 | 15.02 | 142 | 23571 | 25225 | 64449794 |
Acute kidney injury | 233.86 | 15.02 | 511 | 23202 | 448729 | 64026290 |
Right ventricular failure | 195.86 | 15.02 | 113 | 23600 | 21358 | 64453661 |
Pulmonary hypertension | 165.98 | 15.02 | 133 | 23580 | 43006 | 64432013 |
Dyspnoea | 161.23 | 15.02 | 603 | 23110 | 718071 | 63756948 |
Oedema | 133.96 | 15.02 | 167 | 23546 | 91768 | 64383251 |
Hypokalaemia | 126.81 | 15.02 | 188 | 23525 | 121715 | 64353304 |
Drug ineffective | 124.70 | 15.02 | 78 | 23635 | 840169 | 63634850 |
Oedema peripheral | 123.69 | 15.02 | 252 | 23461 | 210065 | 64264954 |
Cardiac failure | 111.10 | 15.02 | 185 | 23528 | 132188 | 64342831 |
Hypotension | 104.24 | 15.02 | 342 | 23371 | 380632 | 64094387 |
Off label use | 97.56 | 15.02 | 56 | 23657 | 632750 | 63842269 |
Gastrointestinal haemorrhage | 75.85 | 15.02 | 157 | 23556 | 132155 | 64342864 |
Chronic kidney disease | 74.55 | 15.02 | 99 | 23614 | 57820 | 64417199 |
Blood creatinine increased | 73.06 | 15.02 | 157 | 23556 | 135625 | 64339394 |
Renal failure | 72.61 | 15.02 | 187 | 23526 | 181501 | 64293518 |
Transfusion | 68.15 | 15.02 | 55 | 23658 | 17939 | 64457080 |
Death | 67.88 | 15.02 | 353 | 23360 | 482352 | 63992667 |
Acute respiratory failure | 66.82 | 15.02 | 87 | 23626 | 49847 | 64425172 |
Calcium deficiency | 66.28 | 15.02 | 20 | 23693 | 718 | 64474301 |
Cardiac failure acute | 61.99 | 15.02 | 50 | 23663 | 16294 | 64458725 |
Atrial fibrillation | 59.20 | 15.02 | 167 | 23546 | 170922 | 64304097 |
Dyspnoea exertional | 59.07 | 15.02 | 101 | 23612 | 73629 | 64401390 |
Blood potassium increased | 56.22 | 15.02 | 58 | 23655 | 25922 | 64449097 |
Weight increased | 55.03 | 15.02 | 188 | 23525 | 213160 | 64261859 |
Hypoxia | 53.33 | 15.02 | 107 | 23606 | 88042 | 64386977 |
Pulmonary oedema | 53.08 | 15.02 | 100 | 23613 | 78574 | 64396445 |
Blood urea increased | 53.05 | 15.02 | 73 | 23640 | 44080 | 64430939 |
Blood potassium decreased | 50.36 | 15.02 | 68 | 23645 | 40331 | 64434688 |
Dehydration | 49.89 | 15.02 | 184 | 23529 | 216579 | 64258440 |
Neutropenia | 48.46 | 15.02 | 14 | 23699 | 239610 | 64235409 |
Hospitalisation | 47.55 | 15.02 | 93 | 23620 | 75114 | 64399905 |
Glomerular filtration rate decreased | 46.57 | 15.02 | 46 | 23667 | 19526 | 64455493 |
Orthopnoea | 45.79 | 15.02 | 33 | 23680 | 9101 | 64465918 |
Infusion related reaction | 45.67 | 15.02 | 4 | 23709 | 164463 | 64310556 |
Rheumatoid arthritis | 45.61 | 15.02 | 4 | 23709 | 164290 | 64310729 |
Generalised oedema | 44.12 | 15.02 | 46 | 23667 | 20807 | 64454212 |
Hyperkalaemia | 43.39 | 15.02 | 107 | 23606 | 101022 | 64373997 |
Polyuria | 42.36 | 15.02 | 36 | 23677 | 12607 | 64462412 |
Metabolic alkalosis | 42.12 | 15.02 | 23 | 23690 | 3905 | 64471114 |
Electrolyte imbalance | 41.85 | 15.02 | 49 | 23664 | 25194 | 64449825 |
Hypovolaemia | 39.85 | 15.02 | 38 | 23675 | 15448 | 64459571 |
Syncope | 39.82 | 15.02 | 138 | 23575 | 157497 | 64317522 |
Pain in jaw | 38.27 | 15.02 | 60 | 23653 | 40695 | 64434324 |
Cardiorenal syndrome | 37.75 | 15.02 | 15 | 23698 | 1235 | 64473784 |
Arthralgia | 37.29 | 15.02 | 66 | 23647 | 442194 | 64032825 |
Gout | 36.22 | 15.02 | 42 | 23671 | 21371 | 64453648 |
Urine sodium decreased | 36.01 | 15.02 | 10 | 23703 | 266 | 64474753 |
Urine chloride decreased | 35.18 | 15.02 | 8 | 23705 | 91 | 64474928 |
Brain natriuretic peptide increased | 34.70 | 15.02 | 26 | 23687 | 7607 | 64467412 |
Febrile neutropenia | 34.36 | 15.02 | 13 | 23700 | 187644 | 64287375 |
Venous pressure jugular increased | 34.16 | 15.02 | 14 | 23699 | 1249 | 64473770 |
Cor pulmonale | 33.83 | 15.02 | 16 | 23697 | 2009 | 64473010 |
Hyponatraemia | 33.32 | 15.02 | 125 | 23588 | 148214 | 64326805 |
Joint swelling | 33.14 | 15.02 | 19 | 23694 | 215363 | 64259656 |
BRASH syndrome | 32.93 | 15.02 | 10 | 23703 | 367 | 64474652 |
Cellulitis | 32.92 | 15.02 | 92 | 23621 | 93565 | 64381454 |
Azotaemia | 32.88 | 15.02 | 25 | 23688 | 7477 | 64467542 |
Treatment failure | 32.00 | 15.02 | 3 | 23710 | 116813 | 64358206 |
Oxygen therapy | 31.94 | 15.02 | 16 | 23697 | 2277 | 64472742 |
Respiratory failure | 31.50 | 15.02 | 130 | 23583 | 161053 | 64313966 |
Necrotising oesophagitis | 30.72 | 15.02 | 11 | 23702 | 679 | 64474340 |
Ascites | 30.26 | 15.02 | 69 | 23644 | 61932 | 64413087 |
Asthenia | 30.19 | 15.02 | 264 | 23449 | 427780 | 64047239 |
Chronic left ventricular failure | 29.91 | 15.02 | 11 | 23702 | 733 | 64474286 |
Product use in unapproved indication | 29.51 | 15.02 | 14 | 23699 | 176604 | 64298415 |
Torsade de pointes | 29.27 | 15.02 | 34 | 23679 | 17329 | 64457690 |
Chronic obstructive pulmonary disease | 29.23 | 15.02 | 74 | 23639 | 70974 | 64404045 |
Alopecia | 27.89 | 15.02 | 13 | 23700 | 165677 | 64309342 |
Paracentesis | 27.53 | 15.02 | 12 | 23701 | 1247 | 64473772 |
International normalised ratio increased | 27.07 | 15.02 | 77 | 23636 | 79090 | 64395929 |
Oxygen consumption increased | 26.33 | 15.02 | 18 | 23695 | 4563 | 64470456 |
Atrial flutter | 26.27 | 15.02 | 34 | 23679 | 19346 | 64455673 |
Condition aggravated | 25.88 | 15.02 | 229 | 23484 | 372197 | 64102822 |
Dermatitis exfoliative | 25.87 | 15.02 | 25 | 23688 | 10327 | 64464692 |
Rash | 25.53 | 15.02 | 85 | 23628 | 458464 | 64016555 |
Venous pressure jugular decreased | 25.17 | 15.02 | 6 | 23707 | 85 | 64474934 |
Arthropathy | 24.56 | 15.02 | 7 | 23706 | 120960 | 64354059 |
Blood sodium decreased | 24.41 | 15.02 | 41 | 23672 | 29441 | 64445578 |
Cholecystitis | 24.39 | 15.02 | 33 | 23680 | 19603 | 64455416 |
Pericardial effusion | 24.14 | 15.02 | 48 | 23665 | 39206 | 64435813 |
Peripheral swelling | 23.97 | 15.02 | 145 | 23568 | 209008 | 64266011 |
Chest pain | 23.58 | 15.02 | 158 | 23555 | 235822 | 64239197 |
Pulmonary arterial pressure increased | 23.25 | 15.02 | 16 | 23697 | 4100 | 64470919 |
White blood cell count decreased | 22.78 | 15.02 | 15 | 23698 | 157822 | 64317197 |
Contraindicated product administered | 22.34 | 15.02 | 6 | 23707 | 107823 | 64367196 |
Left ventricular failure | 22.31 | 15.02 | 21 | 23692 | 8396 | 64466623 |
Musculoskeletal stiffness | 21.78 | 15.02 | 9 | 23704 | 123197 | 64351822 |
Hypertension | 21.53 | 15.02 | 39 | 23674 | 259222 | 64215797 |
Blood loss anaemia | 21.43 | 15.02 | 26 | 23687 | 13866 | 64461153 |
Renal impairment | 21.16 | 15.02 | 102 | 23611 | 134915 | 64340104 |
Pericardial haemorrhage | 20.86 | 15.02 | 15 | 23698 | 4121 | 64470898 |
Respiratory disorder | 20.83 | 15.02 | 43 | 23670 | 36068 | 64438951 |
Malignant neoplasm progression | 20.35 | 15.02 | 8 | 23705 | 112863 | 64362156 |
Renal disorder | 20.27 | 15.02 | 42 | 23671 | 35323 | 64439696 |
Completed suicide | 20.25 | 15.02 | 32 | 23681 | 224382 | 64250637 |
Discomfort | 19.87 | 15.02 | 3 | 23710 | 80875 | 64394144 |
Blood pressure systolic decreased | 19.64 | 15.02 | 20 | 23693 | 8800 | 64466219 |
Bone density decreased | 19.36 | 15.02 | 21 | 23692 | 9931 | 64465088 |
Vascular parkinsonism | 19.22 | 15.02 | 5 | 23708 | 103 | 64474916 |
Localised oedema | 19.18 | 15.02 | 18 | 23695 | 7173 | 64467846 |
Pulmonary arterial wedge pressure increased | 19.17 | 15.02 | 7 | 23706 | 457 | 64474562 |
Oxygen saturation decreased | 19.03 | 15.02 | 84 | 23629 | 107092 | 64367927 |
Systemic lupus erythematosus | 18.79 | 15.02 | 3 | 23710 | 77609 | 64397410 |
Drug hypersensitivity | 18.67 | 15.02 | 37 | 23676 | 237778 | 64237241 |
Abdominal distension | 18.40 | 15.02 | 77 | 23636 | 95917 | 64379102 |
Blood pressure increased | 18.18 | 15.02 | 22 | 23691 | 172530 | 64302489 |
Dizziness | 17.98 | 15.02 | 239 | 23474 | 429924 | 64045095 |
Blood aldosterone abnormal | 17.88 | 15.02 | 4 | 23709 | 42 | 64474977 |
Stomatitis | 17.83 | 15.02 | 9 | 23704 | 109596 | 64365423 |
Gastrointestinal arteriovenous malformation | 17.66 | 15.02 | 8 | 23705 | 911 | 64474108 |
Device leakage | 17.06 | 15.02 | 18 | 23695 | 8248 | 64466771 |
Nasal congestion | 16.61 | 15.02 | 54 | 23659 | 59604 | 64415415 |
Lower respiratory tract infection | 16.58 | 15.02 | 7 | 23706 | 94607 | 64380412 |
Elephantiasis | 16.57 | 15.02 | 3 | 23710 | 9 | 64475010 |
Catheter management | 16.54 | 15.02 | 12 | 23701 | 3343 | 64471676 |
Urine output decreased | 16.49 | 15.02 | 25 | 23688 | 16467 | 64458552 |
Overdose | 16.12 | 15.02 | 21 | 23692 | 159545 | 64315474 |
Interstitial lung disease | 15.93 | 15.02 | 8 | 23705 | 97724 | 64377295 |
Haemodialysis | 15.83 | 15.02 | 25 | 23688 | 17052 | 64457967 |
Hypokalaemic syndrome | 15.68 | 15.02 | 4 | 23709 | 76 | 64474943 |
Injection site pain | 15.52 | 15.02 | 11 | 23702 | 111397 | 64363622 |
Paraesthesia | 15.42 | 15.02 | 16 | 23697 | 134506 | 64340513 |
Pleural effusion | 15.29 | 15.02 | 89 | 23624 | 126470 | 64348549 |
Dyspnoea at rest | 15.28 | 15.02 | 15 | 23698 | 6314 | 64468705 |
None
Source | Code | Description |
---|---|---|
ATC | C03BA08 | CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, EXCL. THIAZIDES Sulfonamides, plain |
ATC | C03EA12 | CARDIOVASCULAR SYSTEM DIURETICS DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION Low-ceiling diuretics and potassium-sparing agents |
FDA PE | N0000175359 | Increased Diuresis |
FDA EPC | N0000175420 | Thiazide-like Diuretic |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D004232 | Diuretics |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D045283 | Natriuretic Agents |
MeSH PA | D049993 | Sodium Chloride Symporter Inhibitors |
CHEBI has role | CHEBI:35498 | diuretics |
CHEBI has role | CHEBI:35674 | antihypertensive drugs |
CHEBI has role | CHEBI:50184 | ion-transport inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Renal Disease with Edema | indication | ||
Peripheral Edema due to Chronic Heart Failure | indication | ||
Pulmonary Edema due to Chronic Heart Failure | indication | ||
Anuria | contraindication | 2472002 | DOID:2983 |
Hypercholesterolemia | contraindication | 13644009 | |
Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
Orthostatic hypotension | contraindication | 28651003 | |
Hypokalemia | contraindication | 43339004 | |
Pregnancy-induced hypertension | contraindication | 48194001 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Sympathectomy | contraindication | 57071006 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Oliguria | contraindication | 83128009 | |
Hyponatremia | contraindication | 89627008 | |
Gout | contraindication | 90560007 | DOID:13189 |
Hypomagnesemia | contraindication | 190855004 | |
Persistent vomiting | contraindication | 196746003 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Severe diarrhea | contraindication | 409587002 | |
Azotemia | contraindication | 445009001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.66 | acidic |
pKa2 | 1.3 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Solute carrier family 12 member 3 | Transporter | INHIBITOR | CHEMBL | CHEMBL | |||||
Solute carrier family 12 member 1 | Transporter | Kd | 8.45 | WOMBAT-PK | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 8.68 | CHEMBL |
ID | Source |
---|---|
D00431 | KEGG_DRUG |
4018161 | VANDF |
C0025854 | UMLSCUI |
CHEBI:64354 | CHEBI |
CHEMBL878 | ChEMBL_ID |
DB00524 | DRUGBANK_ID |
D008788 | MESH_DESCRIPTOR_UI |
4170 | PUBCHEM_CID |
4838 | IUPHAR_LIGAND_ID |
2627 | INN_ID |
TZ7V40X7VX | UNII |
203794 | RXNORM |
1440 | MMSL |
47402 | MMSL |
5101 | MMSL |
d00299 | MMSL |
002310 | NDDF |
22198003 | SNOMEDCT_US |
387123003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0055 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0055 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5050 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5050 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5600 | TABLET | 10 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5600 | TABLET | 10 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6172 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6173 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6174 | TABLET | 10 mg | ORAL | ANDA | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2215 | TABLET | 2.50 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2216 | TABLET | 5 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2217 | TABLET | 10 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6915 | TABLET | 5 mg | ORAL | NDA authorized generic | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6916 | TABLET | 2.50 mg | ORAL | NDA authorized generic | 24 sections |
METOLAZONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7138 | TABLET | 2.50 mg | ORAL | ANDA | 22 sections |
METOLAZONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7139 | TABLET | 5 mg | ORAL | ANDA | 22 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-890 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-931 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-999 | TABLET | 2.50 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
METOLAZONE | Human Prescription Drug Label | 1 | 46708-532 | TABLET | 2.50 mg | ORAL | ANDA | 22 sections |
METOLAZONE | Human Prescription Drug Label | 1 | 46708-533 | TABLET | 5 mg | ORAL | ANDA | 22 sections |
METOLAZONE | Human Prescription Drug Label | 1 | 46708-534 | TABLET | 10 mg | ORAL | ANDA | 22 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-023 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-024 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-431 | TABLET | 2.50 mg | ORAL | ANDA | 12 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-432 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-433 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5056 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5104 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5119 | TABLET | 10 mg | ORAL | ANDA | 23 sections |